STEVENSON, Md., March 07, 2018 -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of Ohr Pharmaceutical, Inc. (Nasdaq:OHRP) (“Ohr” or the “Company”) securities during the period between June 24, 2014 and January 4, 2018, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until April 16, 2018 to seek appointment as lead plaintiff.
If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Ohr securities during the Class Period. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action.
The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that the Company’s lead product, Squalamine, would not produce vision improvements and was commercially not viable.
According to the complaint, following a January 5, 2018 report that topline data from its MAKO study did not meet its primary efficacy endpoint, the value of Ohr shares declined significantly.
If you have suffered a loss in excess of $100,000 from investment in Ohr securities purchased on or after June 24, 2014 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please contact Brower Piven either by email at [email protected] or by telephone at (410) 415-6616.
Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.
CONTACT: Charles J. Piven
Brower Piven, A Professional Corporation
1925 Old Valley Road
Stevenson, Maryland 21153
Telephone: 410-415-6616
[email protected]


Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth
DHL Q2 Profit Jumps 24% as Express Business Drives Growth
OpenAI Restricts Astra AI Over Cyberattack Risks
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations
Nintendo Shares Jump as Switch 2 Sales Boost Earnings
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 



